Johnson & Johnson (JNJ)
186.05
+0.63 (0.34%)
NYSE · Last Trade: Oct 1st, 10:39 PM EDT
Detailed Quote
Previous Close | 185.42 |
---|---|
Open | 186.00 |
Bid | 185.72 |
Ask | 186.05 |
Day's Range | 183.91 - 186.56 |
52 Week Range | 140.68 - 186.56 |
Volume | 13,063,919 |
Market Cap | 489.07B |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | 5.200 (2.79%) |
1 Month Average Volume | 8,813,146 |
Chart
About Johnson & Johnson (JNJ)
Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world. Read More
News & Press Releases
Washington D.C., October 1, 2025 – The United States federal government has officially entered a shutdown today, marking the first such funding lapse in nearly seven years and sending immediate ripples of uncertainty across global financial markets. The inability of Congress to pass appropriations legislation for the 2026 fiscal year
Via MarketMinute · October 1, 2025
As October 1, 2025 dawns, the Federal Reserve finds itself ensnared in a complex economic predicament, grappling with the urgent need to stimulate a faltering labor market while simultaneously battling stubbornly high inflation. This delicate balancing act has been severely complicated by a federal government shutdown, which has effectively cut
Via MarketMinute · October 1, 2025
As the United States government enters a shutdown as of October 1, 2025, financial markets are bracing for a fresh wave of economic uncertainty and volatility. This immediate "risk-off" environment has seen an initial dip in stock futures and a sell-off in the broader market, though historical data suggests the
Via MarketMinute · October 1, 2025
There hasn't been much good news lately for this Johnson & Johnson spinoff.
Via The Motley Fool · October 1, 2025
Pfizer surged after striking a landmark agreement with the Trump administration to lower drug prices and expand U.S. production.
Via The Motley Fool · September 30, 2025
As the third quarter of 2025 drew to a close on September 30, global financial markets demonstrated a remarkable display of resilience, largely shrugging off significant geopolitical uncertainties and the imminent threat of a U.S. federal government shutdown. Major U.S. indices, including the Dow Jones Industrial Average (NYSE:
Via MarketMinute · September 30, 2025
Chicago, IL – September 30, 2025 – As the specter of a U.S. government shutdown hangs heavy over Washington, Chicago Federal Reserve President Austan Goolsbee has issued a stark warning: such an event could severely hamper the central bank's ability to make informed monetary policy decisions, potentially delaying future interest rate
Via MarketMinute · September 30, 2025
Washington D.C. – September 30, 2025 – The financial markets are bracing for significant turbulence as the specter of a government shutdown once again threatens to disrupt the flow of crucial economic data, most notably the highly anticipated monthly jobs report. With Congress deadlocked over budget negotiations, the potential halt in
Via MarketMinute · September 30, 2025
September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between pharmaceutical giant Pfizer (NYSE: PFE) and the U.S. government has sparked a "relief rally" for some major players, the broader market remains
Via MarketMinute · September 30, 2025
New York, NY – September 30, 2025 – AMN Healthcare Services (NYSE: AMN), a leading provider of healthcare staffing solutions, witnessed a significant upward movement in its stock today, reflecting a broader market optimism rippling through the healthcare sector. While AMN's direct stock drivers often stem from company-specific operational successes, today's surge
Via MarketMinute · September 30, 2025
Washington D.C. – September 30, 2025 – The pharmaceutical sector experienced a significant upward surge today, notably led by AbbVie (NYSE: ABBV), following reports of a groundbreaking drug-pricing agreement reached between the White House and a major pharmaceutical player, Pfizer (NYSE: PFE). This development has been widely interpreted by investors as
Via MarketMinute · September 30, 2025
Nanobiotix reported updated Phase 1 trial data for JNJ-1900 in head and neck cancer, showing strong disease control and survival outcomes.
Via Benzinga · September 30, 2025
As the clock ticks towards the critical September 30, 2025, fiscal year-end deadline, Washington D.C. finds itself embroiled in familiar budget battles, once again raising the specter of a U.S. government shutdown. Yet, in a fascinating display of market resilience, Wall Street has largely shrugged off the political
Via MarketMinute · September 30, 2025
As of late September 2025, global financial markets find themselves in a turbulent sea, characterized by persistent volatility and nuanced trends in stock futures. A complex interplay of macroeconomic forces, geopolitical uncertainties, and evolving investor sentiment is driving this dynamic environment, leaving market participants grappling with both opportunities and significant
Via MarketMinute · September 30, 2025
The US dollar experienced a notable weakening against major global currencies today, September 29, 2025, marking a significant shift after a period of sustained strength. This decline is largely attributed to escalating concerns over a potential US government shutdown, which now appears increasingly imminent. The prospect of political gridlock and
Via MarketMinute · September 29, 2025
The U.S. pharmaceutical industry is at the center of a policy maelstrom.
Via Benzinga · September 29, 2025
Johnson & Johnson has increased its dividend every year for 63 consecutive years. It doesn't want to stop.
Via The Motley Fool · September 28, 2025
As the clock ticks towards the September 30, 2025, funding deadline, the United States federal government finds itself perilously close to another shutdown. Congressional leaders remain deadlocked on a spending bill, with crucial negotiations underway to avert what would be the 15th partial federal government shutdown since 1981. This looming
Via MarketMinute · September 29, 2025
The stock is once again nearing an all-time high, but the valuation is untenable.
Via The Motley Fool · September 28, 2025
In a hypothetical scenario playing out just last week, leading up to September 27, 2025, Johnson & Johnson (NYSE: JNJ) experienced a significant stock rally, capturing the attention of investors and market analysts alike. While the specifics of such an event remain a forward-looking conjecture, this article delves into the potential
Via MarketMinute · September 27, 2025
As the clock ticks towards midnight on September 30, 2025, the United States government stands on the precipice of a highly imminent and seemingly unavoidable shutdown. With just days left until the new fiscal year begins, partisan gridlock in Congress has stalled all efforts to pass a funding agreement, setting
Via MarketMinute · September 27, 2025
In the dynamic landscape of financial markets, the allure of finding deeply discounted assets with a strong potential for recovery remains a cornerstone of successful investment strategies. As of September 27, 2025, astute investors are increasingly looking beyond the headlines to identify "beaten-down" and "undervalued" stocks – companies whose market prices
Via MarketMinute · September 27, 2025
Jabil is well-positioned to benefit from the long-term demand driven by AI and its impact on technology at all levels. Analysts are leading this market higher.
Via MarketBeat · September 26, 2025
There is a lot to like about this healthcare company, but that goal might be beyond its powers.
Via The Motley Fool · September 26, 2025
September 26, 2025 – Global financial markets are once again in the throes of uncertainty as the United States unveils a fresh wave of substantial trade tariffs, set to take effect on October 1, 2025. These new duties, targeting sectors from pharmaceuticals to heavy trucks and home furnishings, signal a deepening
Via MarketMinute · September 26, 2025